Menlo Park, CA – According to filings with the U.S. Securities and Exchange Commission, ReCode Therapeutics is raising $80,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, David Lockhart played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ReCode Therapeutics
ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases. The Companys diverse pipeline includes lead programs for cystic fibrosis (CF) caused by nonsense mutations, and primary ciliary dyskinesia (PCD). ReCode has developed a non-viral delivery therapeutic platform that enables it to precisely deliver its medicines safely and effectively. The Company is leveraging its lipid nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.

To learn more about ReCode Therapeutics, visit http://www.recoderx.com/

Contact:
David Lockhart, President and Chief Executive Officer
408-585-1700
https://www.linkedin.com/in/david-lockhart-6b9a40209/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved